UK expands SABR radiotherapy access for prostate cancer patients

The UK National Health Service is expanding the use of Stereotactic Ablative Radiotherapy (SABR) to treat prostate cancer patients. This therapy, previously utilized for lung and brain malignancies, offers a more targeted treatment approach, though the specific clinical outcomes for this expanded cohort remain to be fully documented in large-scale longitudinal studies.